Breaking: Carl Zeiss Meditec (ETR:AFX) Hold Rating Restated by Analysts at Deutsche Bank AG Today; The PT Provided Is EUR 24.80

Share

Carl Zeiss Meditec (ETR:AFX) Rating Reaffirmed

Equity analysts at Deutsche Bank AG now has a EUR 24.80 PT on Carl Zeiss Meditec (ETR:AFX). Deutsche Bank AG and their recent PT would suggest a potential downside of -9.79% from the company’s previous close. The rating has been revealed in recent note on Friday, 18 December.

From a total of 7 analysts covering Carl Zeiss Meditec (ETR:AFX) stock, 4 rate it a ”Buy”, 1 a “Sell”, and 2 a ”Hold”. This means that 57% of the ratings are positive. The highest target price is €29 while the lowest target price is €19.80. The mean of all analyst targets is €26.29 with a -3.98% below today’s (€27.38) stock price. Carl Zeiss Meditec was the topic of 10 analyst reports since August 7, 2015 according to the firm StockzIntelligence Inc. Jefferies downgraded shares on December 17 to “Underperform” rating. Independent Research maintained shares with “Hold” rating and €26 target share price in a report from an August 12. Landesbank upgraded AFX stock in a recent report from October 13 to “Buy” rating. Kepler Cheuvreux upgraded the rating on August 7. Kepler Cheuvreux has a “Buy” rating and a €28 price target on shares. Finally, Berenberg upgraded the stock to “Buy” rating in a report issued on a September 15.

The stock increased 0.26% or EUR 0.07 on December 17, striking EUR 27.38. Approximately 87,171 shares of stock traded hands or 118.03% up from the average. Carl Zeiss Meditec AG (ETR:AFX) has risen 69.05% since May 20, 2015 and is uptrending. It has outperformed by 71.32% the S&P500.

Breaking: Carl Zeiss Meditec (ETR:AFX) Hold Rating Restated by Analysts at Deutsche Bank AG Today; The PT Provided Is EUR 24.80

Carl Zeiss Meditec AG is a Germany-based medical technology solutions supplier. The company has a market cap of 2.08 billion EUR. The Firm operates, along with its subsidiaries, in two business areas: Ophthalmology and Microsurgery. It has 32.12 P/E ratio. The Ophthalmology business area is subdivided into two business units: the Ophthalmology systems unit covers a range of laser and diagnostic systems for ophthalmology, and the Surgical Ophthalmology unit combines the Company’s activities in the field of ophthalmic implants and disposables.

COMMENTS: